JPH0899859A - Skin external agent - Google Patents

Skin external agent

Info

Publication number
JPH0899859A
JPH0899859A JP6261944A JP26194494A JPH0899859A JP H0899859 A JPH0899859 A JP H0899859A JP 6261944 A JP6261944 A JP 6261944A JP 26194494 A JP26194494 A JP 26194494A JP H0899859 A JPH0899859 A JP H0899859A
Authority
JP
Japan
Prior art keywords
extract
rutin
water
skin
soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP6261944A
Other languages
Japanese (ja)
Other versions
JP3460100B2 (en
Inventor
Ichiro Sasaki
一郎 佐々木
Akiyoshi Takayama
明美 高山
Shinji Kobayashi
伸次 小林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kose Corp
Original Assignee
Kose Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kose Corp filed Critical Kose Corp
Priority to JP26194494A priority Critical patent/JP3460100B2/en
Publication of JPH0899859A publication Critical patent/JPH0899859A/en
Application granted granted Critical
Publication of JP3460100B2 publication Critical patent/JP3460100B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

PURPOSE: To obtain a skin external agent containing a water-soluble rutin and a tyrosinase-activity inhibitor as active components, having excellent beautifying effect, accordingly effective for prevention, improvement, etc., of darkening of skin, spots and freckles caused by sunburn, etc., and excellent in stability and safety. CONSTITUTION: This external agent contains (A) a water-soluble rutin [preferably, α-glycosylrutin of the formula (R is glucose, mannose, etc.); the content of rutin is 10-85wt.%] and (B) a tyrosinase-activity inhibitor [e.g. cysteine, an extract of SOUHAKUHI (bark of Morus bombycis) or an extract of TOUKI (root of Angelica acutiloba)] as active components. The content of the component A is preferably 0.00001-5wt.% in terms of rutin. That of the component B is preferably 0.001-5% in term of dried solid. Further, α-glycosylrutin of the formula is obtained e.g. by mixing rutin with starchiness such as dextrin followed by an enzymatic reaction.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、水溶性ルチンとチロシ
ナーゼ活性阻害剤の一種又は二種以上とを有効成分とし
て含有し、美白効果に優れ、安定性及び安全性の高い新
規な皮膚外用剤に関する。
The present invention relates to a novel external preparation for skin which contains water-soluble rutin and one or more kinds of tyrosinase activity inhibitors as active ingredients and has an excellent whitening effect and high stability and safety. Regarding

【0002】[0002]

【従来の技術】従来、皮膚の色黒、シミ、ソバカスの防
止などの美容効果を得る目的で美白化粧料が広く用いら
れており、このような美白化粧料には美白薬剤として主
にアスコルビン酸、グルタチオン、コロイドイオウ等が
配合されている。しかしながら、アスコルビン酸は酸化
を受けやすいため、一定の効果の発現が期待し難く、ま
たグルタチオンやコロイドイオウは特有の異臭及び沈殿
等が生じるという欠点があった。
2. Description of the Related Art Conventionally, whitening cosmetics have been widely used for the purpose of obtaining beauty effects such as preventing dark skin, stains and freckles on the skin, and ascorbic acid is mainly used as a whitening agent for such whitening cosmetics. , Glutathione, colloidal sulfur, etc. are blended. However, since ascorbic acid is susceptible to oxidation, it is difficult to expect a certain effect to be exerted, and glutathione and colloidal sulfur have a particular offensive odor and precipitation.

【0003】このため、最近では、広く自然界からの美
白薬剤の探究が行われているが、その美白効果は必ずし
も十分満足出来るものとは言い切れず、より高い美白効
果を有する皮膚外用剤が求められている。
For this reason, recently, whitening agents have been widely searched from the natural world, but the whitening effect cannot be said to be sufficiently satisfactory, and a skin external preparation having a higher whitening effect is desired. Has been.

【0004】一方、ルチンは、ソバの全草のほか、ジャ
ガイモ、アスパラガス、アンズ、サクランボ、トマト、
イチジク、柑橘類、アズキなどの野菜や果物、又ハチミ
ツ、緑茶などにも広く含まれる化合物であり、酸化防
止、紫外線吸収、血管補強等の種々の作用が知られてい
るが、水にはほとんど溶けないことから、あまり利用さ
れないものであった。
On the other hand, rutin is not only whole buckwheat but also potato, asparagus, apricot, cherry, tomato,
It is a compound widely contained in vegetables and fruits such as figs, citrus fruits and adzuki beans, as well as honey and green tea, and is known to have various actions such as antioxidant, UV absorption, and blood vessel reinforcement, but it is almost soluble in water. Since it was not there, it was not used very often.

【0005】そこで、ルチンの水溶性を高め、これを化
粧料に配合利用することも試みられてきた(特開平3−
27293号、同3−58790号、同3−11529
2号、同3−275607号、同3−275608号
等)。
Therefore, it has been attempted to enhance the water solubility of rutin and use it in a cosmetic composition (Japanese Patent Laid-Open No. 3-301).
No. 27293, No. 3-58790, No. 3-11529.
No. 2, No. 3-275607, No. 3-275608, etc.).

【0006】[0006]

【発明が解決しようとする課題】しかしながら、水溶性
ルチン単独ではその効果を十分に発揮させることは難し
く、また目的達成の為には多量に配合する必要があり、
水溶性ルチンによる着色が外観上問題になることもあっ
た。
However, it is difficult to sufficiently exert the effect of water-soluble rutin alone, and it is necessary to add a large amount of water-soluble rutin in order to achieve the object.
Coloring with water-soluble rutin sometimes caused a problem in appearance.

【0007】[0007]

【課題を解決するための手段】本発明者らは従来の皮膚
外用剤よりも、より美白効果に優れ、しかも安定性、安
全性の高い皮膚外用剤を提供するために鋭意研究を重ね
た結果、水溶性ルチンとチロシナーゼ活性阻害剤の一種
又は二種以上とを併用すれば、美白効果が相乗的に増大
し、しかも、これらを配合した皮膚外用剤は安定性、安
全性に優れたものであることを見出し、本発明を完成し
た。
Means for Solving the Problems As a result of intensive studies, the present inventors have conducted extensive studies in order to provide a skin external preparation that is more stable than the conventional skin external preparation and has a high whitening effect and high stability and safety. If one or more of water-soluble rutin and tyrosinase activity inhibitor are used in combination, the whitening effect is synergistically increased, and a skin external preparation containing these is excellent in stability and safety. The present invention has been completed and the present invention has been completed.

【0008】すなわち、本発明は次の成分(A)及び
(B) (A)水溶性ルチン (B)チロシナーゼ活性阻害剤 を有効成分として含有することを特徴とする皮膚外用剤
を提供するものである。
That is, the present invention provides a skin external preparation characterized by containing the following components (A) and (B) (A) water-soluble rutin (B) tyrosinase activity inhibitor as an active ingredient. is there.

【0009】本発明の(A)成分である水溶性ルチン
は、上記の如くルチンの水溶性を高めたものであれば良
く、特に限定するものではないが、例えば、ルチンにデ
キストリン等の澱粉質を混合し、酵素反応によりルチン
にグルコース、マルトース、マルトトリオース、マルト
テトラオース等の転移した一般式化1で示されるα−グ
リコシルルチンが好適に用いられる。これらは1種又は
2種以上組み合わせて用いても良く、(A)成分中のル
チン含量が10〜85重量%のものが好ましい。
The water-soluble rutin which is the component (A) of the present invention is not particularly limited as long as the water solubility of rutin is increased as described above. For example, rutin is a starch substance such as dextrin. Α-glycosyl rutin represented by the general formula 1 in which glucose, maltose, maltotriose, maltotetraose and the like are transferred to rutin by mixing the above-mentioned substances with an enzyme reaction is preferably used. These may be used alone or in combination of two or more, and the rutin content in the component (A) is preferably 10 to 85% by weight.

【0010】[0010]

【化1】 [Chemical 1]

【0011】本発明の化粧料における(A)成分(水溶
性ルチン)の含有量は、ルチン換算で、好ましくは0.
00001〜5重量%(以下単に「%」で示す)(未反
応デキストリンを含んだ粉末として好ましくは0.00
01〜10%、より好ましくは0.01〜5%)であ
る。
The content of the component (A) (water-soluble rutin) in the cosmetic composition of the present invention is preferably 0.
00001 to 5% by weight (hereinafter simply referred to as "%") (preferably 0.00 as a powder containing unreacted dextrin)
01-10%, more preferably 0.01-5%).

【0012】(A)成分の含有量が0.00001%よ
り少ないと十分な効果は得られないことがあり、また、
5%を超えて配合してもそれ以上の効果の増大は見られ
ない。
If the content of the component (A) is less than 0.00001%, a sufficient effect may not be obtained, and
Even if the content exceeds 5%, the effect is not further increased.

【0013】一方、本発明の(B)成分であるチロシナ
ーゼ活性阻害剤としては、システイン及びその誘導体
(例えばN,N’−ジアセチルシスチンジメチル等)並
びにその塩、ソウハクヒ抽出物、トウキ抽出物、イブキ
トラノオ抽出物、クララ抽出物、サンザシ抽出物、シラ
ユリ抽出物、ホップ抽出物、ノイバラ抽出物、ヨクイニ
ン抽出物等が挙げられる。
On the other hand, examples of the tyrosinase activity inhibitor which is the component (B) of the present invention include cysteine and its derivatives (for example, N, N'-diacetylcystine dimethyl) and salts thereof, soybean extract, Toki extract and Ibuki. Tranoo extract, Clara extract, hawthorn extract, white lily extract, hop extract, Neubara extract, Yokuinin extract and the like can be mentioned.

【0014】この(B)成分のうち、ヨクイニン抽出物
は、イネ科のハトムギ(Coix lacryma-jobi L.var.ma-y
uen (ROMAN) STAPF)の種皮を除いた種子等から抽出して
得られるものである。
Among the components (B), the Yokuinin extract is a coix lacryma-jobi L.var.ma-y
uen (ROMAN) STAPF) is obtained by extracting from seeds and the like excluding the seed coat.

【0015】またソウハクヒ、トウキ、イブキトラノ
オ、クララ、サンザシ、ホップ、ノイバラ、シラユリの
抽出物は、それら植物の使用部は特に限定されず、それ
ぞれの葉、枝、茎、花、果実、根等を用い抽出すること
ができるが、就中、イブキトラノオは根茎、クララは
根、サンザシ、ノイバラは果実、ホップは花、シラユリ
は鱗茎を利用することが好ましい。
[0015] The extract of Sohakuhi, Touki, Ibukitoranoo, Clara, Hawthorn, hops, Neubara, and white lily is not particularly limited in the use part of these plants, and leaves, branches, stems, flowers, fruits, roots, etc. Among them, it is preferable to use rhizomes for Ibukitoranoo, roots for Clara, hawthorn and Neubarra for fruits, flowers for hops, and bulbs for white lily, among others.

【0016】上記各植物体から(B)成分を得るための
抽出方法は特に限定されないが、例えば種々の適当な溶
媒を用いて室温又は加温下で抽出することができる。抽
出溶媒としては、例えば水;メチルアルコール、エチル
アルコール等の低級一価アルコール;プロピレングリコ
ール、1,3−ブチレングリコール等の液状多価アルコ
ール;酢酸エチル等の低級アルキルエステル;ベンゼ
ン、ヘキサン等の炭化水素;エチルエーテル等のエーテ
ル類等の一種又は二種以上を用いることができる。これ
らのうちでも、水又は水溶性溶媒、特に水、エチルアル
コール、グリセリン、1,3−ブチレングリコールの一
種又は二種以上の混合溶媒が好ましい。
The extraction method for obtaining the component (B) from each of the above-mentioned plants is not particularly limited, but it can be extracted, for example, using various suitable solvents at room temperature or under heating. Examples of the extraction solvent include water; lower monohydric alcohols such as methyl alcohol and ethyl alcohol; liquid polyhydric alcohols such as propylene glycol and 1,3-butylene glycol; lower alkyl esters such as ethyl acetate; carbonization such as benzene and hexane. Hydrogen; one or more ethers such as ethyl ether may be used. Among these, water or a water-soluble solvent, particularly water, ethyl alcohol, glycerin, 1,3-butylene glycol, or a mixed solvent of two or more thereof is preferable.

【0017】以上のような条件で得られる植物起源の
(B)成分は、抽出された溶液のまま用いても良いが、
さらに必要により濃縮、濾過等の処理をしたものを適宜
使い分けて用いることができる。
The component (B) of plant origin obtained under the above conditions may be used as an extracted solution,
Further, if necessary, those which have been subjected to treatments such as concentration and filtration can be appropriately used and used.

【0018】これら(B)成分は、単独又は二種以上を
組み合わせて用いることができ、皮膚外用剤における含
有量が乾燥固形分として0.0001〜10%、特に
0.001〜5%となるように配合するのが好ましい。
0.0001%未満では充分な美白効果が得られず、1
0%を超えて配合してもその効果は増大せず、また場合
によっては着色等の問題を生じることがあり好ましくな
い。
These components (B) can be used alone or in combination of two or more, and the content in the external preparation for skin is 0.0001 to 10%, particularly 0.001 to 5% as a dry solid content. It is preferable to mix them as follows.
If it is less than 0.0001%, a sufficient whitening effect cannot be obtained, and 1
Even if blended in excess of 0%, the effect does not increase, and in some cases, problems such as coloring may occur, such being undesirable.

【0019】本発明の皮膚外用剤は、上記必須成分であ
る(A)成分と(B)成分とを配合し、常法に従って製
造することができ、乳液、クリーム、化粧水、パック、
軟膏、分散液、顆粒、洗浄料等の剤形とすることができ
る。
The external preparation for skin of the present invention can be produced by mixing the above-mentioned essential components (A) and (B) according to a conventional method, and can be used as an emulsion, cream, lotion, pack,
It may be in the form of an ointment, a dispersion, granules, a detergent or the like.

【0020】さらに、本発明の皮膚外用剤には、前記必
須成分の他、必要に応じて通常の皮膚外用剤に用いられ
る水性成分、粉末、界面活性剤、油剤、保湿剤、アルコ
ール類、pH調整剤、防腐剤、色素、酸化防止剤、増粘
剤、香料等を適宜配合することができる。
Further, the external preparation for skin of the present invention contains, in addition to the above-mentioned essential components, aqueous components, powders, surfactants, oils, humectants, alcohols, and pH, which are used in usual external preparations for skin. A regulator, an antiseptic, a dye, an antioxidant, a thickener, a fragrance and the like can be appropriately added.

【0021】[0021]

【実施例】次に試験例及び実施例を挙げて本発明をさら
に詳細に説明するが、本発明はこれらになんら制約され
るものではない。
The present invention will be described in more detail with reference to Test Examples and Examples, but the present invention is not limited to these.

【0022】試験例1 チロシナーゼ活性阻害試験:下記方法により、本発明の
(A)及び(B)成分の単独又はそれらを組み合わせた
試料のチロシナーゼ活性阻害率を調べた。すなわち、各
試料に酵素溶液[シグマ社製、28,000単位のチロ
シナーゼ10mgを0.1Mリン酸緩衝液(pH6.
8)20mlに溶解したもの]0.1mlを加え、さら
に0.1Mリン酸緩衝液(pH6.8)を加え4.0m
lとし、これを25℃にて10分間インキュベートし
た。
Test Example 1 Tyrosinase activity inhibition test: The tyrosinase activity inhibition rate of the samples of the components (A) and (B) of the present invention alone or in combination thereof was examined by the following method. That is, to each sample, an enzyme solution [manufactured by Sigma, 28,000 units of tyrosinase 10 mg was added to a 0.1 M phosphate buffer solution (pH 6.
8) Dissolved in 20 ml] 0.1 ml was added, and 0.1 M phosphate buffer (pH 6.8) was further added to 4.0 m.
1 and this was incubated at 25 ° C. for 10 minutes.

【0023】次いで、これにあらかじめ25℃に保って
おいた基質溶液[L−DOPA(東京化成)198.0
mgを0.1Mリン酸緩衝液(pH6.8)100ml
に溶解したもの]1.0mlを加え、10分間反応せし
めた。反応後、475nmにおける吸光度(ODS )を
測定した。同様に、加熱失活させた前記酵素を用いて反
応させた時の吸光度(ODHE)及び試料無添加のときの
吸光度(ODB )を測定し、次式よりチロシナーゼ活性
の活性阻害率を算出した。
Then, the substrate solution [L-DOPA (Tokyo Kasei) 198.0, which was previously kept at 25 ° C., was used.
100 mg of 0.1 M phosphate buffer (pH 6.8)
1.0 ml) was added and reacted for 10 minutes. After the reaction, the absorbance (ODS) at 475 nm was measured. Similarly, the absorbance (ODHE) at the time of reaction using the enzyme deactivated by heating and the absorbance (ODB) at the time when no sample was added were measured, and the activity inhibition rate of tyrosinase activity was calculated from the following formula.

【0024】[0024]

【式1】 この結果を表1に示す。[Formula 1] Table 1 shows the results.

【0025】[0025]

【表1】 [Table 1]

【0026】表1から明らかな如く、水溶性ルチンとチ
ロシナーゼ活性阻害剤を組み合わせた場合には、水溶性
ルチン又はチロシナーゼ活性阻害剤を単独で用いた場合
よりチロシナーゼ活性阻害作用が高く、相乗的な美白効
果を示した。
As is clear from Table 1, when the water-soluble rutin and the tyrosinase activity inhibitor are combined, the tyrosinase activity inhibitory action is higher than that when the water-soluble rutin or the tyrosinase activity inhibitor is used alone, and a synergistic effect is obtained. It showed a whitening effect.

【0027】実施例1 表2に示す組成の乳液を製造し、美白効果について評価
した。この結果を表3に示す。
Example 1 An emulsion having the composition shown in Table 2 was produced and evaluated for its whitening effect. The results are shown in Table 3.

【0028】[0028]

【表2】 [Table 2]

【0029】<製法> A.(6)〜(16)、(20)及び(21)を加熱混
合し、70℃に保つ。 B.(1)〜(5)、(17)及び(18)を加熱混合
し、70℃に保つ。 C.BをAに加えて混合し、さらに(19)を加え、均
一に乳化し、30℃まで冷却して乳液を得る。
<Production Method> A. (6) to (16), (20) and (21) are mixed by heating and kept at 70 ° C. B. (1) to (5), (17) and (18) are mixed by heating and kept at 70 ° C. C. B is added to A and mixed, and (19) is further added to emulsify uniformly and cooled to 30 ° C. to obtain an emulsion.

【0030】<美白効果試験>23〜44才の女性45
名をパネルとし、毎日、朝と夜の2回、洗顔後に本発明
品1〜8及び比較品1〜4の乳液を、各人2品ずつそれ
ぞれ適量顔面に12週間にわたって塗布することによ
り、使用テストを行ない、次の基準で評価した。 評価基準; 有 効: シミ、ソバカスが目立たなくなった。 やや有効: シミ、ソバカスがあまり目立たなくなっ
た。 無 効: 変わらない。
<Whitening effect test> Female 45 aged 23 to 44
The name is used as a panel, and the products of the invention products 1 to 8 and the comparative products 1 to 4 are applied to the face in an appropriate amount for 12 weeks each day after washing twice daily in the morning and at night. The test was conducted and evaluated according to the following criteria. Evaluation Criteria: Effective: Spots and freckles disappeared. Slightly effective: Spots and freckles are less noticeable. Ineffective: No change.

【0031】[0031]

【表3】 [Table 3]

【0032】表3から明らかな如く、水溶性ルチンとチ
ロシナーゼ活性阻害剤を組み合わせて配合した本発明の
乳液(試料1〜8)は、これらを全く含まない比較品1
と比較した場合はもとより、水溶性ルチンまたはチロシ
ナーゼ活性阻害剤を単独で配合した比較品2〜4と比べ
ても、シミ・ソバカスを目立たなくする効果に優れ、顕
著な美白効果を示した。
As is clear from Table 3, the emulsions of the present invention (Samples 1 to 8) in which the water-soluble rutin and the tyrosinase activity inhibitor were combined in combination were comparative products 1 containing none of them.
Not only when compared with Comparative Examples 2 to 4 in which water-soluble rutin or a tyrosinase activity inhibitor was blended alone, the effect of making spots and freckles inconspicuous was excellent and a remarkable whitening effect was exhibited.

【0033】実施例2 化粧水:次に示す処方及び下記製法で化粧水を得た。本
発明の化粧水は優れた美白効果を有するものであった。 <処方> (配合量)% (1)グリセリン 5.0 (2)1,3−ブチレングリコール 6.5 (3)ポリオキシエチレンソルビタン 1.2 モノラウリン酸エステル(20E.O.) (4)エチルアルコール 8.0 (5)水溶性ルチン(注1) 0.01 (6)ヨクイニンエキス(注2)(乾燥固形分として) 0.05 (7)防腐剤 適量 (8)香料 適量 (9)精製水 残量 (注1)ルチンにマルトース一残基を転移して得られた、ルチン含量として8 0%のもの (注2)丸善製薬社製
Example 2 Lotion: Lotion was obtained by the following formulation and the following production method. The lotion of the present invention had an excellent whitening effect. <Prescription> (Blending amount)% (1) Glycerin 5.0 (2) 1,3-butylene glycol 6.5 (3) Polyoxyethylene sorbitan 1.2 Monolauric acid ester (20EO) (4) Ethyl Alcohol 8.0 (5) Water-soluble rutin (Note 1) 0.01 (6) Yokuinin extract (Note 2) (as dry solids) 0.05 (7) Preservative proper amount (8) Perfume proper amount (9) Purification Water balance (Note 1) 80% rutin content obtained by transferring one maltose residue to rutin (Note 2) Maruzen Pharmaceutical Co., Ltd.

【0034】<製法> A.(3)、(4)、(7)及び(8)を混合溶解す
る。 B.(1)、(2)、(5)、(6)及び(9)を混合
溶解する。 C.AとBを混合して均一にし、化粧水を得た。
<Production Method> A. (3), (4), (7) and (8) are mixed and dissolved. B. (1), (2), (5), (6) and (9) are mixed and dissolved. C. A and B were mixed and made uniform to obtain a lotion.

【0035】実施例3 クリーム:次に示す処方及び下記製法でクリームを得
た。本発明のクリームは優れた美白効果を有するもので
あった。 <処方> (配合量)% (1)ミツロウ 6.0 (2)セタノール 5.0 (3)還元ラノリン 5.0 (4)スクワラン 30.0 (5)グリセリンモノステアレート 4.0 (6)親油型モノステアリン酸グリセリン 2.0 (7)ポリオキシエチレンソルビタン 2.0 モノラウリン酸エステル(20E.O.) (8)水溶性ルチン(注1) 1.0 (9)ソウハクヒエキス(注2)(乾燥固形分として) 0.2 (10)防腐剤 0.3 (11)香料 0.05 (12)精製水 残量 (注1)ルチンにマルトース残基を転移して得られた、ルチン含量として40 %のもの (注2)丸善製薬社製
Example 3 Cream: A cream was obtained by the following formulation and the following production method. The cream of the present invention had an excellent whitening effect. <Prescription> (Blended amount)% (1) Beeswax 6.0 (2) Cetanol 5.0 (3) Reduced lanolin 5.0 (4) Squalane 30.0 (5) Glycerin monostearate 4.0 (6) Lipophilic glyceryl monostearate 2.0 (7) Polyoxyethylene sorbitan 2.0 Monolauric acid ester (20 EO) (8) Water-soluble rutin (Note 1) 1.0 (9) Sophoraceae extract (Note 2) ) (As dry solids) 0.2 (10) Preservative 0.3 (11) Perfume 0.05 (12) Purified water Remaining amount (Note 1) Rutin obtained by transferring maltose residue to rutin 40% content (* 2) Maruzen Pharmaceutical Co., Ltd.

【0036】<製法> A.(1)〜(7)、(10)及び(11)を混合し、
加熱して70℃に保つ。 B.(8)、(9)及び(12)を混合し、加熱して7
0℃に保つ。 C.AにBを加え、混合した後、冷却してクリームを得
た。
<Production Method> A. (1) to (7), (10) and (11) are mixed,
Heat and keep at 70 ° C. B. Mix (8), (9) and (12) and heat to 7
Keep at 0 ° C. C. B was added to A, mixed, and then cooled to obtain a cream.

【0037】実施例4 洗浄料:次に示す処方及び下記製法で洗浄料を得た。本
発明の洗浄料は優れた美白効果を有するものであった。 <処方> (配合量)% (1)ステアリン酸 10.0 (2)パルミチン酸 8.0 (3)ミリスチン酸 12.0 (4)ラウリン酸 4.0 (5)オレイルアルコール 1.5 (6)精製ラノリン 1.0 (7)香料 0.1 (8)防腐剤 0.2 (9)グリセリン 18.0 (10)水酸化カリウム 6.0 (11)水溶性ルチン(注1) 0.2 (12)ホップエキス(注2) 0.01 (13)精製水 残量 (注1)ルチンにグルコース一残基を転移して得られた、ルチン含量として8 0%のもの (注2)香栄興業社製
Example 4 Cleaning Agent: A cleaning agent was obtained by the following formulation and the following production method. The detergent of the present invention had an excellent whitening effect. <Prescription> (Blended amount)% (1) Stearic acid 10.0 (2) Palmitic acid 8.0 (3) Myristic acid 12.0 (4) Lauric acid 4.0 (5) Oleyl alcohol 1.5 (6) ) Purified lanolin 1.0 (7) Perfume 0.1 (8) Preservative 0.2 (9) Glycerin 18.0 (10) Potassium hydroxide 6.0 (11) Water-soluble rutin (Note 1) 0.2 (12) Hop extract (* 2) 0.01 (13) Purified water Remaining amount (* 1) Transferring one glucose residue to rutin, having a rutin content of 80% (* 2) Fragrance Made by Eiko Industry Co., Ltd.

【0038】<製法> A.(9)〜(10)及び(13)を混合し、加熱して
70℃に加熱する。 B.(1)〜(6)及び(8)を混合し、70℃に加熱
する。 C.AにBを加え、暫く70℃に保ち、けん化反応が終
了してから、50℃まで冷却し、(7)、(11)及び
(12)を加え、冷却して洗浄料を得た。
<Production Method> A. (9) to (10) and (13) are mixed and heated to 70 ° C. B. Mix (1) to (6) and (8) and heat to 70 ° C. C. B was added to A and maintained at 70 ° C. for a while, and after the saponification reaction was completed, it was cooled to 50 ° C., (7), (11) and (12) were added and cooled to obtain a cleaning agent.

【0039】[0039]

【発明の効果】以上詳述した如く、本発明の皮膚外用剤
は、美白効果に優れているので、日やけなどによる皮膚
の黒色化、シミ、ソバカスの防止・改善等に有効であ
る。さらに本発明の皮膚外用剤は、安定でしかも安全で
あるため、安心して使用することができる。 以 上
As described above in detail, since the external preparation for skin of the present invention has an excellent whitening effect, it is effective in preventing and improving the blackening of the skin due to sunburn and the like, and the prevention of stains and freckles. Furthermore, since the external preparation for skin of the present invention is stable and safe, it can be used with confidence. that's all

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 FI 技術表示箇所 A61K 31/70 ADA 35/78 C 8217−4C N 8217−4C J 8217−4C H 8217−4C V 8217−4C E 8217−4C ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 6 Identification code Office reference number FI Technical indication location A61K 31/70 ADA 35/78 C 8217-4C N 8217-4C J 8217-4C H 8217-4C V 8217-4C E 8217-4C

Claims (3)

【特許請求の範囲】[Claims] 【請求項1】 次の成分(A)及び(B) (A)水溶性ルチン (B)チロシナーゼ活性阻害剤 を有効成分として含有することを特徴とする皮膚外用
剤。
1. A skin external preparation containing the following components (A) and (B) (A) water-soluble rutin (B) tyrosinase activity inhibitor as an active ingredient.
【請求項2】 水溶性ルチンが、α−グリコシルルチン
である請求項1記載の皮膚外用剤。
2. The external preparation for skin according to claim 1, wherein the water-soluble rutin is α-glycosyl rutin.
【請求項3】 チロシナーゼ活性阻害剤が、システイン
及びその誘導体並びにその塩、ソウハクヒ抽出物、トウ
キ抽出物、イブキトラノオ抽出物、クララ抽出物、サン
ザシ抽出物、シラユリ抽出物、ホップ抽出物、ノイバラ
抽出物及びヨクイニン抽出物から選ばれたものである請
求項1記載の皮膚外用剤。
3. A tyrosinase activity inhibitor comprises cysteine and its derivatives and salts thereof, sophoraceae extract, adzuki bean extract, ibukitrano extract, clara extract, hawthorn extract, syringa lichen extract, hop extract, and Neubara extract. The external preparation for skin according to claim 1, which is selected from the extract and Yokuinin extract.
JP26194494A 1994-09-30 1994-09-30 Whitening agent Expired - Lifetime JP3460100B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP26194494A JP3460100B2 (en) 1994-09-30 1994-09-30 Whitening agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP26194494A JP3460100B2 (en) 1994-09-30 1994-09-30 Whitening agent

Publications (2)

Publication Number Publication Date
JPH0899859A true JPH0899859A (en) 1996-04-16
JP3460100B2 JP3460100B2 (en) 2003-10-27

Family

ID=17368848

Family Applications (1)

Application Number Title Priority Date Filing Date
JP26194494A Expired - Lifetime JP3460100B2 (en) 1994-09-30 1994-09-30 Whitening agent

Country Status (1)

Country Link
JP (1) JP3460100B2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000007544A (en) * 1998-06-16 2000-01-11 Matsukawa Kagaku:Kk Cosmetic
US6214352B1 (en) 2000-01-06 2001-04-10 Matsukawa Kagaku Co., Ltd. Tyrosinase inhibiting agent
KR100328975B1 (en) * 1999-09-03 2002-03-20 서경배 Whitening composition including the myrrh extract
US6521267B1 (en) 1998-06-08 2003-02-18 Fytokem Prtoducts, Inc. Tyrosinase inhibitors from plants
WO2008026507A1 (en) * 2006-09-01 2008-03-06 Sapporo Breweries Limited Skin whitening agent
KR100825839B1 (en) * 2000-07-19 2008-04-28 가부시키가이샤 시세이도 External preparations for beautifying the skin
JP2009280550A (en) * 2008-05-26 2009-12-03 Sanei Gen Ffi Inc Tyrosinase activity inhibitor
KR101441291B1 (en) * 2013-12-13 2014-09-17 주식회사 코스메카코리아 Cosmetic composition comprising extract of Baby brier and Lespedeza cuneata for whitening and antioxdiant

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105687026B (en) * 2016-01-25 2018-07-27 张馨文 A kind of spot-eliminating composition and the preparation method and application thereof

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6521267B1 (en) 1998-06-08 2003-02-18 Fytokem Prtoducts, Inc. Tyrosinase inhibitors from plants
JP2000007544A (en) * 1998-06-16 2000-01-11 Matsukawa Kagaku:Kk Cosmetic
KR100328975B1 (en) * 1999-09-03 2002-03-20 서경배 Whitening composition including the myrrh extract
US6214352B1 (en) 2000-01-06 2001-04-10 Matsukawa Kagaku Co., Ltd. Tyrosinase inhibiting agent
KR100825839B1 (en) * 2000-07-19 2008-04-28 가부시키가이샤 시세이도 External preparations for beautifying the skin
WO2008026507A1 (en) * 2006-09-01 2008-03-06 Sapporo Breweries Limited Skin whitening agent
JP2009280550A (en) * 2008-05-26 2009-12-03 Sanei Gen Ffi Inc Tyrosinase activity inhibitor
KR101441291B1 (en) * 2013-12-13 2014-09-17 주식회사 코스메카코리아 Cosmetic composition comprising extract of Baby brier and Lespedeza cuneata for whitening and antioxdiant

Also Published As

Publication number Publication date
JP3460100B2 (en) 2003-10-27

Similar Documents

Publication Publication Date Title
JP3805798B2 (en) Cosmetics
EP1172091A1 (en) Skin dyeing compositions containing flavylium salt compounds non substituted in position 3
JPH0899820A (en) Skin external agent
JP2903412B2 (en) Cosmetics
JP3170070B2 (en) External preparation for skin
JP2008239545A (en) Elastase deactivator
JP3480953B2 (en) External preparation for skin
JP3460100B2 (en) Whitening agent
JPH0930946A (en) Beautifying and whitening dermal preparation for external use
JP2005029490A (en) Tyrosinase inhibitor, active oxygen retarder and skin care preparation for external use
JPH0930954A (en) Beautifying and whitening dermal preparation for external use
JPH0812560A (en) Skin external preparation
JP3584489B2 (en) External preparation for skin
JPH0812561A (en) Beautifying and whitening skin preparation for external use
JP3480954B2 (en) External preparation for skin
JPH10279428A (en) Cosmetic
JPH10182404A (en) Preparation for external use for skin
JPH0812549A (en) Skin external preparation
JP3647296B2 (en) Inhibition of tyrosinase activity and compositions containing the same
JPH0812552A (en) Skin external preparation
JPH05271045A (en) Cosmetic
JPH08175964A (en) Skin preparation for external use
JP4402274B2 (en) Topical skin preparation
JPH0812564A (en) Skin external preparation
JPH0812557A (en) Skin external preparation

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120815

Year of fee payment: 9

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140815

Year of fee payment: 11

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term